Difference between revisions of "Part:BBa K3582023"

 
Line 12: Line 12:
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K3582023 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K3582023 SequenceAndFeatures</partinfo>
 +
 +
===References===
 +
 +
*1] Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. (2011, December 1). PubMed
 +
Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/
 +
*2] Poth, A. G. (2013, May 7). Cyclotides as Grafting Frameworks for Protein Engineering and Drug Design
 +
Applications. PubMed. https://pubmed.ncbi.nlm.nih.gov/23893608/
 +
*3] 2. Camarero, J. A. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development.
 +
MDPI. https://www.mdpi.com/2227-9059/7/2/31/htm#B31-biomedicines-07-00031
  
  

Revision as of 13:35, 20 October 2020


Cyclotide Kalata B1 domain with strep II tag

The biobrick codes for cyclotide kalata B1 protein domain consisting of first 5 loops of the cyclotide construct. This part is created to allow insertion of peptide sequences in the 6th loop.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 29

References

  • 1] Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. (2011, December 1). PubMed

Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/

  • 2] Poth, A. G. (2013, May 7). Cyclotides as Grafting Frameworks for Protein Engineering and Drug Design

Applications. PubMed. https://pubmed.ncbi.nlm.nih.gov/23893608/

  • 3] 2. Camarero, J. A. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development.

MDPI. https://www.mdpi.com/2227-9059/7/2/31/htm#B31-biomedicines-07-00031